Grand Pharmaceutical

What Grand Pharmaceutical does

Grand Pharmaceutical Group Limited is a China-based pharmaceutical company headquartered in Wuhan that operates across pharmaceutical preparations, medical devices, biotechnology products, and nuclear medicine for anti-tumor diagnosis and treatment. Its core technology platform centers on nuclear medicine applied to oncology diagnostics and therapy, alongside a portfolio of conventional pharmaceutical preparations and medical devices, with secondary exposure to nutritional ingredients including taurine for energy drinks, dietary supplements, infant nutrition, and premium pet foods. The company has secured US FDA authorization to proceed with clinical trials for a nuclear medicine-based tumor diagnosis drug, signaling an effort to validate and commercialize its proprietary oncology platform in regulated Western markets.

Commercially, Grand Pharmaceutical generates revenue through a mix of proprietary product sales and licensing/commercialization partnerships. Its most prominent commercial vehicle is the exclusive partnership with Tarsus Pharmaceuticals for Greater China, under which Grand Pharma received approval and executed the 2026 commercial launch of TP-03 (lotilaner ophthalmic solution) for Demodex blepharitis. The Tarsus relationship extends into the pipeline, covering TP-04 (Ocular Rosacea, Phase II) and TP-05 (Lyme disease prevention, Phase II planned Q2 2026), positioning the company as the regional commercialization channel for an evolving set of ophthalmic and infectious disease assets. GTM motion is predominantly channel-driven, leveraging in-licensed assets for regional distribution rather than building standalone sales infrastructure in every therapeutic area.

Name

Grand Pharmaceutical

Website

https://grandpharma.cn

Company type

Private

Operating status

Operating

Short description

Grand Pharmaceutical is a Wuhan-based Chinese pharmaceutical company developing nuclear medicine oncology diagnostics, pharmaceutical preparations, medical devices, and biotechnology products, and serving as Tarsus Pharmaceuticals' exclusive Greater China commercialization partner for TP-03 and related ophthalmic pipeline assets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Preparations and Biotechnology Products

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Pharmaceutical preparations
• Nuclear medicine oncology
• Biotechnology products
• Ophthalmic pharmaceuticals
• Medical devices

Headquarters

HQ city

Wuhan

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Licensing and Commercialization Partnership: Grand Pharmaceutical generates revenue through licensing and commercialization partnerships, including milestone payments for regulatory approvals and commercial launch activities in Greater China.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Grand Pharmaceutical develops and supplies pharmaceutical preparations, medical devices, and biotechnology products, with a core focus on nuclear medicine for anti-tumor diagnosis and treatment. Its commercial offerings include the TP-03 (Lotilaner ophthalmic solution) treatment for Demodex blepharitis commercialized in Greater China via a Tarsus Pharmaceuticals partnership, plus nutritional ingredients such as taurine for energy drinks, dietary supplements, infant nutrition, and pet foods.

Product overview

Grand Pharmaceutical Group Limited operates as a pharmaceutical preparations, medical devices, and biotechnology products company. The portfolio includes nuclear medicine products for anti-tumor diagnosis and treatment, commercially launched ophthalmic pharmaceuticals (TP-03 for Demodex blepharitis), and pipeline products (TP-04 for Ocular Rosacea, TP-05 for Lyme disease prevention). The company also has exposure to nutritional ingredients including taurine for energy drinks, dietary supplements, infant nutrition, and premium pet foods.

Differentiator

Problem solved

Functional benefit

Products and services

• TP-03 (Lotilaner ophthalmic solution) Lotilaner ophthalmic solution commercialized by Grand Pharma in Greater China for the treatment of Demodex blepharitis, developed by partner Tarsus Pharmaceuticals.
• Tumor Diagnosis Drug A nuclear medicine-based tumor diagnosis drug that has received US FDA approval to proceed with clinical trials in the United States, intended for healthcare providers and patients requiring oncology diagnostics.
• Nutritional Ingredients (e.g., Taurine) Taurine and related nutritional ingredients supplied to manufacturers of energy drinks, dietary supplements, infant nutrition products, and premium pet foods.

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Tarsus PharmaceuticalscoreStrategic or Co-development Partner · 25 March 2026Grand Pharmaceutical acts as the Chinese partner for Tarsus Pharmaceuticals, receiving approval to commercialize TP-03 (a treatment for Demodex blepharitis) in Greater China. The partnership resulted in a $15 million milestone payment to Tarsus following regulatory approval, with Grand Pharma handling commercial launch activities in the Chinese market.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Hutchmed (China) Limited: China-rooted oncology-focused biotech with global trial programs and partnership/out-licensing deals (e.g., AstraZeneca, Eli Lilly). Highly comparable on the China-oncology R&D plus out-licensing business model.
• Fosun Pharma: Diversified Chinese pharmaceutical group with branded generics, specialty pharma, and biotech, plus an active strategy of in-licensing international assets for the China market. Highly comparable to Grand Pharma's licensing-plus-distribution model.
• Sino Biopharmaceutical Limited: One of the largest China-based specialty pharmaceutical groups with oncology and branded specialty franchises across cardiovascular, oncology, and respiratory. Highly comparable as a diversified Chinese specialty pharma operating across multiple therapeutic areas, including partnerships and in-house R&D.
• CSPC Pharmaceutical Group: Major Hong Kong-listed Chinese pharma with strength in oncology, neurology, and anti-infectives, including a biological products franchise. Compares directly on the combination of branded specialty pharma and biotech/nuclear-adjacent development scale in the same China market.
• China Isotope & Radiation Corporation: China's dominant nuclear medicine and isotope products group, with direct overlap in radiopharmaceuticals for oncology diagnosis and treatment. The most direct nuclear-medicine peer for Grand Pharma's proprietary anti-tumor nuclear diagnostics franchise.
• Lantheus Holdings, Inc. US specialty radiopharmaceutical company focused on diagnostic imaging agents and emerging therapeutic radiopharmaceuticals. The closest pure-play comparator for Grand Pharma's nuclear medicine oncology diagnostics and treatment platform.
• Tarsus Pharmaceuticals, Inc. US-based specialty pharma focused on ophthalmology products including TP-03 for Demodex blepharitis. Grand Pharma's exclusive Greater China partner and the originator of the TP-03/TP-04/TP-05 pipeline currently being commercialized in China.
• Jiangsu Hengrui Medicine Co., Ltd. China's largest specialty pharma innovator with deep oncology and specialty-care pipelines plus commercial infrastructure across hospitals. Directly comparable as a Chinese branded-specialty pharma with proprietary R&D and an active international licensing strategy.
• Shanghai Pharmaceuticals Holding Co., Ltd. Large integrated Chinese pharma combining pharmaceutical manufacturing, distribution, and R&D with both branded specialty and generics exposure. Comparable as a diversified Chinese pharma with broad distribution and partnered/in-licensed specialty products.

Broad incumbents

• Novartis AG: Global pharma major with the Pluvicto/Lutathera radioligand franchise and broad oncology portfolio. Relevant as a broad incumbent shaping the nuclear medicine and oncology competitive landscape in which Grand Pharma operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grand Pharmaceutical